news
New drug for ALS ready for clinical trials
Previous studies have suggested that a gene therapy drug may be used to treat ALS...
List view / Grid view
In Vivo
news
Promising drug targets for t-cell lymphoblastic leukaemia
Silencing the gene behind the production of HSP90, a target in the HSF1 pathway, effectively kills leukaemia cells, without affecting healthy cells...
article
Exploring horizons in 3D microscopy: what the future holds
The microscope slide is flat (2D), but the world around us is not – despite the flat-earth theories. We need volume information about our samples, ideally with high resolution in all three dimensions as well as over time – the fourth dimension...
news
Key role of PI3Ky in Chagas disease described
The expression of PI3Ky increases during infection by T.cruzi, providing an essential response controlling the parasite and avoiding inflammation...
article
Genomics in drug development and safety testing; from target identification to genomic toxicology
In the annual report of the Chief Medical Officer, 1 Dame Sally Davies has declared that we are part of ‘generation genome’ – the era in which we reap the rewards of our advances in genomic technologies and improvements in our understanding of the whole genome in human health.
article
Streamlining drug discovery assays for cancer and cardiovascular disease
For lead optimisation, target-based assays are still the most affordable means of rapidly performing fast iterations and remain core to screening. However, the desire for biological relevance is driving ongoing growth in cell-based assays.
article
Expert view: How high-content platforms keep pace with the changing face of cell-based drug screening
For the next generation of cell biologists, 3D cell culture and analysis has opened doors to taking applied research one step further.
article
Expert view: Improving R&D productivity with novel screening approaches
The pursuit of improved R&D productivity rates coupled with decreased cycle times has dominated pharmaceutical discourse in recent years.
news
Charles River Laboratories announces extended relationship with The Michael J. Fox Foundation
Extension includes new project to phenotype Parkinson’s disease models and the continuation of LRRK2 research.
webinar
Biomarker endpoints for Parkinson’s disease
26 April 2018 | By Charles River Laboratories
This webinar provides a comprehensive review of the validation data from established and novel animal models of Parkinson’s disease.
article
High throughput flow cytometry for multifactorial evaluation of novel therapeutic candidates using an innovative in vitro immunooncology screening platform
This recent webinar focused on the role of IntelliCyt’s iQue Screener PLUS platform as a high throughput suspension cell screening platform to facilitate simultaneous assessment of multiple parameters, while using minimal sample volumes.
article
Expert view: Toward physiological relevance in drug discovery and development
Physiologically relevant screening models have become increasingly important in assay development and the screening of drug candidates.
article
Streamlining drug discovery assays for cancer and cardiovascular disease
Declining R&D productivity is a key challenge in the pharmaceutical industry. To increase the success rate of candidate drugs entering the clinical phase, companies must address the early stages of drug discovery.
news
Pro72Arg gene variant increases tumour cell metabolism
Scientists have found a mechanism through which mutant p53 enhances metastasis by controlling tumour metabolism...
news
Charles River Laboratories announces new tumour model compendium
The Compendium provides scientists an online resource to help design efficient in vitro and in vivo oncology research studies.
